UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst
Jefferies upgraded Vanda Pharmaceuticals (NASDAQ: VNDA) from Hold to Buy and raised the price target from $3.50 to $6.00.
Jefferies commented, "We're finally giving credit for tasimelteon given 1) surprisingly good recent Non24 Ph.3 data w/clinical sleep efficacy which likely improves FDA receptivity, 2) orphan pricing not confounded by ‘depression' efforts, and 3) approaching regulatory catalysts. We still think it's far from a slam dunk, but even conservatively discounted Tasi contribution is likely big upside from current negative EV level."
Vanda Pharmaceuticals closed at $3.95 on Wednesday.
Latest Ratings for VNDA
|Jun 2014||Empire Asset Management||Initiates Coverage on||Sell|
|Feb 2014||Piper Jaffray||Maintains||Overweight|
|Nov 2013||Piper Jaffray||Initiates Coverage on||Overweight|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.